Medline Inc. Reports Third Quarter 2026 Financial Results

Medline reported third-quarter 2026 net sales of $7.856 billion, up 10.4% year over year, while net income fell 1.2% to $318 million. Adjusted diluted EPS was $0.44, above analyst expectations. The company raised its full-year organic sales growth guidance to 10.0%–10.5% and reaffirmed adjusted EBITDA guidance of $3.3 billion–$3.4 billion. Its board authorized up to $1 billion in share repurchases, and Medline prepaid $750 million of principal on its 2033 refinancing term loan; management cited customer expansion and new customer signings as growth drivers.